The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

The Federal Trade Commission has published a report that found pharmacy benefit managers Caremark Rx LLC (CVS), Express Scripts and OptumRx marked up numerous specialty generic drugs by ...

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

During a roughly five-year span, CVS Health, Cigna, and UnitedHealth benefited the most from increasing prices for generic drugs that treated illnesses such as HIV and cancer. Some of the price hikes ...

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

Prescription benefit managers have been under growing scrutiny from state and federal regulators who have accused them of creating pharmacy deserts by steering consumers to their own pharmacies and ...